Rapport Therapeutics, Inc. (RAPP)

Market Cap	1.80B +364.1%
Revenue (ttm)	20.00M
Net Income	-107.28M
EPS	-2.56
Shares Out	47.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	174,249
Open	36.89
Previous Close	36.70
Day's Range	36.38 - 37.89
52-Week Range	7.73 - 42.27
Beta	n/a
Analysts	Strong Buy
Price Target	55.90 (+48.2%)
Earnings Date	May 7, 2026

About RAPP

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorde...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 7, 2024
• Employees: 84
• Stock Exchange: NASDAQ
• Ticker Symbol: RAPP
• Website: https://www.rapportrx.com

Analyst Summary

According to 11 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price target is $55.9, which is an increase of 48.20% from the latest price.

Price Target

$55.9

(48.20% upside)

Analyst Consensus: Strong Buy